About Nucleus RadioPharma

Nucleus RadioPharma is a full-service Contract Development and Manufacturing Organization (CDMO) specializing in targeted radiotherapies. They build robust and reliable clinical and commercial supply chains to support radiopharmaceutical innovators from concept to market. The company provides purpose-built facilities and expertise to accelerate the development, manufacturing, and delivery of radiotherapeutics safely and efficiently.

```xml <problem> The radiopharmaceutical industry faces bottlenecks in manufacturing capacity and supply chain logistics, which limits the availability of targeted radiotherapies. The short half-lives of radioactive isotopes require rapid manufacturing, release, and delivery, making efficient supply chains crucial. Existing manufacturing constraints hinder the ability to bring new radiotheranostics to market and deliver life-saving treatments to patients in a timely manner. </problem> <solution> Nucleus RadioPharma is a contract development and manufacturing organization (CDMO) focused on building robust clinical and commercial supply chains for targeted radiotherapies. The company provides end-to-end services, leveraging advanced manufacturing infrastructure and regulatory expertise to accelerate the development and delivery of radiopharmaceuticals. By establishing manufacturing facilities in proximity to medical centers and distribution hubs, Nucleus RadioPharma aims to mitigate supply chain challenges and ensure timely access to radiotherapies for patients. The CDMO offers flexible services at multiple onboarding points, supporting innovators throughout the product lifecycle. </solution> <features> - Commercial-scale radiopharmaceutical CDMO facilities designed to support pre-clinical, clinical, and commercial stages. - Expertise in product development and regulatory affairs to advance drug candidates. - Manufacturing infrastructure and interconnected resource network for efficient radiotherapy production. - Supply chain networks designed to meet the demands of radioactive isotope-based products. - Focus on client innovations without developing proprietary products. - Facilities located near prominent destination medical centers and key distribution hubs. </features> <target_audience> The primary customers are biotech startups and established pharmaceutical organizations involved in developing targeted radiotherapies. </target_audience> ```

What does Nucleus RadioPharma do?

Where is Nucleus RadioPharma located?

Nucleus RadioPharma is based in United States.

When was Nucleus RadioPharma founded?

Nucleus RadioPharma was founded in 2022.

How much funding has Nucleus RadioPharma raised?

Nucleus RadioPharma has raised $72.1M.

Location

United States

Founded

2022

Funding

$72.1M

Employees

41 employees

Nucleus RadioPharma

United StatesFounded 2022415K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 2 months ago

Funding

$72.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

The radiopharmaceutical industry faces bottlenecks in manufacturing capacity and supply chain logistics, which limits the availability of targeted radiotherapies. The short half-lives of radioactive isotopes require rapid manufacturing, release, and delivery, making efficient supply chains crucial. Existing manufacturing constraints hinder the ability to bring new radiotheranostics to market and deliver life-saving treatments to patients in a timely manner.

Solution

Nucleus RadioPharma is a contract development and manufacturing organization (CDMO) focused on building robust clinical and commercial supply chains for targeted radiotherapies. The company provides end-to-end services, leveraging advanced manufacturing infrastructure and regulatory expertise to accelerate the development and delivery of radiopharmaceuticals. By establishing manufacturing facilities in proximity to medical centers and distribution hubs, Nucleus RadioPharma aims to mitigate supply chain challenges and ensure timely access to radiotherapies for patients. The CDMO offers flexible services at multiple onboarding points, supporting innovators throughout the product lifecycle.

Target Audience

The primary customers are biotech startups and established pharmaceutical organizations involved in developing targeted radiotherapies.

Features

Commercial-scale radiopharmaceutical CDMO facilities designed to support pre-clinical, clinical, and commercial stages.
Expertise in product development and regulatory affairs to advance drug candidates.
Manufacturing infrastructure and interconnected resource network for efficient radiotherapy production.
Supply chain networks designed to meet the demands of radioactive isotope-based products.
Focus on client innovations without developing proprietary products.
Facilities located near prominent destination medical centers and key distribution hubs.